People: Brainstorm Cell Therapuetics Inc (BCLI.OB)
BCLI.OB on OTC BB
0.21USD
17 May 2013
0.21USD
17 May 2013
Price Change (% chg)
$-0.01 (-3.67%)
$-0.01 (-3.67%)
Prev Close
$0.22
$0.22
Open
$0.20
$0.20
Day's High
$0.21
$0.21
Day's Low
$0.20
$0.20
Volume
294,748
294,748
Avg. Vol
182,740
182,740
52-wk High
$0.38
$0.38
52-wk Low
$0.17
$0.17
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Abraham Israeli |
59 | 2010 | Independent Chairman of the Board |
Chaim Lebovits |
43 | 2007 | President |
Alon Natanson |
49 | 2013 | Chief Executive Officer |
Liat Sossover |
44 | 2010 | Chief Financial Officer |
Adrian Harel |
56 | 2013 | Director - Research and Development |
Irit Arbel |
52 | 2004 | Independent Director |
Mordechai Friedman |
60 | 2011 | Independent Director |
Alon Pinkas |
51 | 2010 | Independent Director |
Chen Schor |
40 | 2011 | Independent Director |
Robert Shorr |
59 | 2005 | Independent Director |
Malcolm Taub |
66 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Abraham Israeli |
Dr. Abraham Israeli is Independent Chairman of the Board of Brainstorm Cell Therapeutics Inc. Since November 2009, Dr. Israeli has served as Head of the Department of Health Policy, Health Care Management and Health Economics at the Hebrew University, Hadassah Faculty of Medicine. Since 1996, Dr. Israeli has held the Chair of Dr. Julien Rozan Professorship of Medicine and Health Promotion at the Hebrew University - Hadassah Medical School, Jerusalem. From November 2003 to October 2009, Dr. Israeli served as the Director General of the Israel Ministry of Health. Dr. Israeli holds a M.D. and M.P.H. from Hebrew University, Hadassah Medical School and a Master’s Degree from the Sloan School of Management at Massachusetts Institute of Technology. Dr. Israeli completed residencies in Internal Medicine and in Health-Care Management at Hadassah University Hospital and has certification in both specialties. |
Chaim Lebovits |
Mr. Chaim Lebovits is President of Brainstorm Cell Therapeutics Inc. Mr. Lebovits controls ACC Holdings, a holding company which controls subsidiaries: (i) Shemen Oil and Gas Resources Ltd. ("Shemen"); (ii) ACC Resources; and (iii) ACCBT. ACC Holdings focuses on minerals exploration in West Africa and Israel. ACC Resources holds 10 permits for gold exploration in Burkina Faso. Shemen holds the Shemen License offshore Israel, which has contingent and prospective resources of over 250 million barrels of oil. ACCBT focuses on new and emerging biotechnologies. Mr. Lebovits has been at the forefront of mining and natural resource management in the African region for close to a decade. |
Alon Natanson |
Mr. Alon Natanson is Chief Executive Officer of Brainstorm Cell Therapeutics Inc. Prior to joining the Company and the Subsidiary, Mr. Natanson led as well as early-stage companies, in the fields of life science, high-tech, and retail. Prior positions include Director of Marketing and Finance at Teva Pharmaceuticals, Copaxone® division, where he was involved in commercialization of patented therapeutics for multiple sclerosis, establishing the division and planning and executing its international strategy and product launch. Since 2008 Mr. Natanson served as President and Chief Executive Officer of Procognia (TASE: PRCG), a biotechnology company specializing in glycobiology and biopharmaceutical analytics. |
Liat Sossover |
Ms. Liat Sossover is Chief Financial Officer of Brainstorm Cell Therapeutics Inc. From 2001 until June 2010, Ms. Sossover served as the Vice President of Finance of ForeScout Technologies, International. In such role, Ms. Sossover managed all financial and accounting aspects. Prior to that, Ms. Sossover served as VP of Finance and Secretary of Maximal Innovative Intelligence, which was acquired by Microsoft. She has held positions as Chief Financial Officer at RT Set, which is now part of Vizrt and Financial Controller for BVR Technologies, which later was acquired by Esterline Technologies. Ms. Sossover holds an MBA from Edinburgh University, and a Bachelor's degree in Accounting & Economics from Ben Gurion University. |
Adrian Harel |
Dr. Adrian Harel, Ph.D., is Director - Research and Development of Brainstorm Cell Therapeutics Inc. Dr. Harel previously served as the Company’s Chief Operating Officer and Acting Chief Executive Officer. From 2009 until 2010, Dr. Harel set up Da-Ta Biotech Ltd, a consulting and advisory business focused on early stage biotech companies. Also during 2010, Dr. Harel provided consulting services to KMBY LTD in connection with a medical device in the orthopedic field. From 2008 through 2010, Dr. Harel served as Chief Executive Officer of Meditor Pharmaceuticals Ltd. and Aminolab Technologies 2000 Ltd., which are focused on the production of new ethical drugs. From 2003 through 2007, Dr. Harel served as Chief Operating Officer of Sepal Pharma Ltd. and Molecular Cytomics Ltd. |
Irit Arbel |
Dr. Irit Arbel is Independent Director of Brainstorm Cell Therapeutics Inc. She has been an active Board Member of the Company since May 2004 and also served initially as President for six months. From 2009 through 2011, Dr. Arbel served as Chairperson of Real Aesthetics Ltd., a company specializing in cellulite ultrasound treatment, and BRH Medical, developer of medical devices for wound healing. She was also Director of M & A at RFB Investment House, a private investment firm focusing on early stage technology related companies. Previously, Dr. Arbel was President and CEO of Pluristem Life Systems, and prior to that, Israeli Sales Manager of Merck, Sharp & Dohme. Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology, after performing research in the area of Multiple Sclerosis. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel’s Institute of Technology. |
Mordechai Friedman |
Mr. Mordechai Friedman is Independent Director of Brainstorm Cell Therapeutics Inc., since April 4, 2011. He is Chairman of the Audit Committee of the Board. Since 2010, Mr. Friedman has served as Chief Executive Officer of Triple M Management and Investments Ltd. From 2007 through 2010, Mr. Friedman served as the Chairman of the Board of The Israel Electric Corp. From 2005 to 2007, Mr. Friedman served as Deputy Chairman and Chief Executive Officer of Brightman, Almagor & Zohar, Inc., a division of Deloitte Touche Tohmatsu. Mr. Friedman has been a partner and director in several business ventures and companies in Israel and abroad in the transportation, consumer business, telecommunication and energy industries. He has a B.A. in Economics and Accounting from the Tel Aviv University. Mr. Friedman currently serves as a director of the following private companies: (i) Electra Consumer Products; (ii) Tel-Hashomer-Medical Research; (iii) Triple M Management and Investments Ltd.; (iv) Mordechai Friedman Blue and White Management Services Ltd.; and (v) Double M Management and Investments Ltd. |
Alon Pinkas |
Mr. Alon Pinkas is Independent Director of Brainstorm Cell Therapeutics Inc. Mr. Pinkas served as the Israeli Consul General to New York from 2000 to 2004 and is an internationally respected foreign affairs analyst. Mr. Pinkas currently serves as an Adviser at Tigris Financial Group and the Rhodium Group. Mr. Pinkas currently serves as a director for Ormat Industries Limited, B.G.I. Investments (1961) Ltd. and Agri-Invest Ltd. Mr. Pinkas has a Bachelors Degree in Political Science from The Hebrew University of Jerusalem and a Masters Degree in Politics from Georgetown University. |
Chen Schor |
Mr. Chen Schor, CPA, is Independent Director of Brainstorm Cell Therapeutics Inc. Mr. Schor led multiple licensing and M&A transactions with companies such as GlaxoSmithKline, Amgen, Pfizer, Bayer, Merck-Serono and OncoGeneX Pharmaceuticals, and raised funds from reputable investors. Mr. Schor has a broad range of experience in multiple therapeutic areas including Neurology, Respiratory, Oncology, Auto-Immune, Genetic Diseases, and Women’s Health. In addition to the global business development at Teva Pharmaceuticals, Mr. Schor played a key role in building early stage companies to regulatory approvals, IPOs and M&As. From March 2009 until September 2011, Mr. Schor served as Vice President of Business Development, global branded products at Teva Pharmaceuticals. Prior to joining Teva, Mr. Schor was Chief Business Officer at Predix Pharmaceuticals from December 2003 until March 2009. Prior to joining Predix, Mr. Schor was a Partner at Yozma Venture Capital from September 1998 until December 2003, managing the fund’s investments in biotechnology and medical device companies. Mr. Schor previously held positions at Arthur Anderson and BDO consultants and holds an MBA, B.A. in biology, B.A. in economics and is a Certified Public Accountant (CPA). |
Robert Shorr |
Dr. Robert G. Shorr is Independent Director of Brainstorm Cell Therapeutics Inc. Since 1999, Dr. Shorr has served as Chief Executive Officer and Chief Science Officer of Cornerstone Pharmaceuticals, a bio technology company. Since 1998, he has also been a member of the Department of Biomedical Engineering at SUNY Stony Brook, where he also serves as Director of Business Development for the university’s Center for Advanced Technology. He has served as trustee at the Tissue Engineering Charities, Imperial College, London since 1999. From 1999 until 2005, Dr. Shorr was Vice-President of Science and Technology (CSO) of United Therapeutics, a NASDAQ listed company. Prior to 1998 he held management positions at Enzon Inc., a NASDAQ listed company, and AT Biochem of which he was also founder. Dr. Shorr also served on the Board of Directors of Biological Delivery Systems Inc., a NASDAQ listed company. Dr. Shorr holds both a Ph.D. and a D.I.C. from the University of London, Imperial College of Science and Technology as well as a B.Sc. from SUNY Buffalo. |
Malcolm Taub |
Mr. Malcolm Taub is Independent Director of Brainstorm Cell Therapeutics Inc. Since October 2010, Mr. Taub has been a Partner at Davidoff Malito & Hutcher LLP, a full service law and government relations firm. From 2001 to September 30, 2010, Mr. Taub was the Managing Member of Malcom S. Taub LLP, a law firm which practiced in the areas of commercial litigation, among other practice areas. Mr. Taub also works on art transactions, in the capacity as an attorney and a consultant. Mr. Taub has also served as a principal of a firm which provides consulting services to private companies going public in the United States. Mr. Taub has acted as a consultant to the New York Stock Exchange in its Market Surveillance Department. Mr. Taub acts as a Trustee of The Gateway Schools of New York and The Devereux Glenholme School in Washington, Connecticut. Mr. Taub has served as an adjunct professor at Long Island University, Manhattan Marymount College and New York University Real Estate Institute. Mr. Taub holds a B.A. degree from Brooklyn College and a J.D. degree from Brooklyn Law School. Mr. Taub formerly served on the Board of Directors of Safer Shot, Inc. (formerly known as Monumental Marketing Inc.), a company which trades on the Pink Sheets. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Abraham Israeli |
-- |
Chaim Lebovits |
59,342 |
Alon Natanson |
-- |
Liat Sossover |
144,000 |
Adrian Harel |
385,026 |
Irit Arbel |
-- |
Mordechai Friedman |
-- |
Alon Pinkas |
-- |
Chen Schor |
-- |
Robert Shorr |
-- |
Malcolm Taub |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Abraham Israeli |
0 | 0 |
Chaim Lebovits |
0 | 0 |
Alon Natanson |
0 | 0 |
Liat Sossover |
0 | 0 |
Adrian Harel |
0 | 0 |
Irit Arbel |
0 | 0 |
Mordechai Friedman |
0 | 0 |
Alon Pinkas |
0 | 0 |
Chen Schor |
0 | 0 |
Robert Shorr |
0 | 0 |
Malcolm Taub |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
TAUB MALCOLM S |
130,000 | $0.00 |
SHORR ROBERT GL |
130,000 | $0.00 |
SHORR ROBERT GL |
130,000 | $0.00 |
TAUB MALCOLM S |
130,000 | $0.00 |
SHORR ROBERT GL |
98,333 | $0.26 |
SHORR ROBERT GL |
10,000 | $0.27 |
SCHOR CHEN |
923,374 | $0.00 |
SHORR ROBERT GL |
95,000 | $0.30 |
SHORR ROBERT GL |
105,000 | $0.31 |
TAUB MALCOLM S |
100,000 | $0.46 |
TAUB MALCOLM S |
130,000 | $0.00 |
SHORR ROBERT GL |
130,000 | $0.00 |
TAUB MALCOLM S |
108,333 | $0.00 |
SHORR ROBERT GL |
108,333 | $0.00 |
ACC INTERNATIONAL HOLDINGS LTD |
100,000 | $0.28 |
TAUB MALCOLM S |
33,023 | $0.28 |
ACC INTERNATIONAL HOLDINGS LTD |
100,000 | $0.27 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
